Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug users

Addict Biol. 2016 Jul;21(4):885-94. doi: 10.1111/adb.12241. Epub 2015 Mar 26.

Abstract

A major problem in the treatment of addiction is predicting and preventing relapse following a rehabilitation program. Recently, in preclinical rodent studies dehydroepiandrosterone (DHEA) was found to markedly improve the resistance to drug reuse. In a double-blind, placebo-controlled study, we examined the effect of DHEA on relapse rates in adult polydrug users taking part in a detoxification program enriched with intensive psychosocial interventions and aftercare. During treatment, participants (79 percent males, mean age 28) consumed DHEA (100 mg/day) or placebo daily for at least 30 days. Of the 121 initial volunteers, 64 participated for at least 1 month. While in treatment, DHEA reduced negative affect on the Positive and Negative Affect Scale (F = 4.25, P = 0.04). Furthermore, in a 16-month follow-up, we found that reuse rates in the DHEA condition were about a third compared with placebo (12 versus 38 percent; χ(2) = 5.03, P = 0.02). DHEA treatment also resulted in an increase in DHEA sulfate (DHEA-S) 1 month following treatment, and the level of DHEA-S predicted relapse in the follow-up assessment.

Keywords: Cortisol; DHEA; decision making; drug addiction; relapse.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Affect / drug effects*
  • Decision Making / drug effects*
  • Dehydroepiandrosterone / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Israel
  • Male
  • Recurrence
  • Substance-Related Disorders / drug therapy*
  • Substance-Related Disorders / psychology
  • Treatment Outcome
  • Young Adult

Substances

  • Adjuvants, Immunologic
  • Dehydroepiandrosterone